Radiofrequency Endometrial Ablation or Uterine Artery Embolization for Treatment of Adenomyosis-r… (NCT07195305) | Clinical Trial Compass
RecruitingNot Applicable
Radiofrequency Endometrial Ablation or Uterine Artery Embolization for Treatment of Adenomyosis-related Abnormal Uterine Bleeding
France230 participantsStarted 2026-04-17
Plain-language summary
The present study aims to compare the efficacy (menstrual blood loss, pain, quality of life) and the safety (complications, recovery) of each conservative intervention (RFA, UAE) versus hysterectomy for the treatment of adenomyosis-related abnormal uterine bleeding, up to 2 years
Who can participate
Age range30 Years – 50 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Premenopausal women aged 30 to 50 years
* Women who had at least 3 prior months failed medical therapy, or a contraindication to medical therapy, or refused medical therapy for adenomyosis-related AUB
* Symptomatic pure internal adenomyosis or dominant adenomyosis (with less than 5 concurrent uterine fibroids type 3-7 \< 5 cm) confirmed by MRI (\< 6 months) according to ESHRE criteria
* AUB defined as a PBAC score \>100 at baseline
* Uterine ultrasound measurement of 6.0-12.0 cm (external os to internal fundus)
* Women with an indication for hysterectomy for adenomyosis-related AUB and accepting hysterectomy
* Highly effective contraception for women of childbearing potential, maintained until the onset of menopause
* Affiliated or beneficiary of health insurance
* Signed informed consent
Exclusion Criteria:
* Uterine cavity abnormality or obstruction confirmed via imaging modalities or hysteroscopy
* Deep infiltrating posterior subperitoneal endometriosis involving contiguous digestive tract structures
* Uterine malignancy within the last five years
* Secreting ovarian tumor
* Atypical endometrial hyperplasia
* Unaddressed high grade cervical intra-epithelial lesions
* Active sexually transmitted disease or pelvic inflammatory disease
* Documented or suspected coagulopathies or long-term blood-thinner medications
* Prior transmural myomectomy or prior endometrial ablation
* Plasma FSH level \> 40 IU/mL
* Any contraindication to angiography (including…
What they're measuring
1
proportion of 2-year clinical success of the intervention